Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis By Sheena Cruz / 06/01/2026
Early Initiation of Ublituximab Treatment is Associated with Improved Disability Outcomes Among Treatment-Naïve Participants in ULTIMATE I and II By admin / 04/17/2024
Ublituximab Significantly Reduces Radiological Disease Activity at 12 Weeks: Post-hoc analysis of Participants with Highly Active Disease in the ULTIMATE I & II Phase 3 Studies By admin / 04/17/2024
Improved Cognitive Processing Speed With Ublituximab in Patients With Highly Active Relapsing Multiple Sclerosis By admin / 06/02/2022
